ARS Pharmaceuticals (SPRY) Revenue & Revenue Breakdown
ARS Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$84.28M
Latest Revenue (Q)
$22.68M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
ARS Pharmaceuticals Revenue by Period
ARS Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $84.28M | -5.46% |
| 2024-12-31 | $89.15M | 297063.33% |
| 2023-12-31 | $30.00K | -97.72% |
| 2022-12-31 | $1.32M | -76.10% |
| 2021-12-31 | $5.51M | -69.13% |
| 2020-12-31 | $17.84M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
ARS Pharmaceuticals generated $84.28M in revenue during NA 2025, up -5.46% compared to the previous quarter, and up 472.54% compared to the same period a year ago.
ARS Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $22.68M | -19.25% |
| 2025-12-31 | $28.09M | -13.58% |
| 2025-09-30 | $32.50M | 106.79% |
| 2025-06-30 | $15.72M | 97.13% |
| 2025-03-31 | $7.97M | -90.79% |
| 2024-12-31 | $86.58M | 4086.70% |
| 2024-09-30 | $2.07M | 313.60% |
| 2024-06-30 | $500.00K | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $10.00K | -50.00% |
| 2023-03-31 | $20.00K | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2022-09-30 | $189.00K | -59.27% |
| 2022-06-30 | $464.00K | -30.02% |
| 2022-03-31 | $663.00K | -12.07% |
| 2021-12-31 | $754.00K | 42.80% |
| 2021-09-30 | $528.00K | -75.00% |
| 2021-06-30 | $2.11M | - |
| 2021-03-31 | $2.11M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | - |
ARS Pharmaceuticals generated $22.68M in revenue during Q1 2026, up -19.25% compared to the previous quarter, and up 26.20% compared to the same period a year ago.
ARS Pharmaceuticals Revenue Breakdown
ARS Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Product | $72.19M | $7.25M |
ARS Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Jun 25 | Dec 24 | Sep 24 |
|---|---|---|---|---|---|
| Product | $17.45M | $59.39M | $12.80M | $6.69M | $568.00K |
ARS Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (100.00%).
ARS Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 |
|---|---|
| UNITED STATES | $72.19M |
| Non-US | $12.09M |
ARS Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (85.66%), and Non-US (14.34%).
Quarterly Revenue by Country
| Country | Mar 26 |
|---|---|
| UNITED STATES | $17.45M |
| DENMARK | $2.78M |
| Non-US | $2.45M |
ARS Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (76.95%), DENMARK (12.24%), and Non-US (10.81%).
ARS Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SPRY | ARS Pharmaceuticals | $84.28M | $22.68M |
| KURA | Kura Oncology | $67.48M | $18.27M |
| NBTX | Nanobiotix | $30.06M | $30.06M |
| LENZ | LENZ Therapeutics | $19.09M | $1.90M |
| ABUS | Arbutus Biopharma | $14.08M | $179.13M |
| PROK | ProKidney | $893.00K | $226.00K |
| RZLT | Rezolute | - | - |
| SVRA | Savara | - | - |
| GHRS | GH Research | - | $80.00K |
| PVLA | Palvella Therapeutics | - | - |
| TYRA | Tyra Biosciences | - | - |